Nasal sprays with corticosteroids deliver medication to the restricted areas including anterior and inferior parts of the nasal cavity. The fluticasone exhalation delivery system (EDS-FLU) has recently been proved to improve care by increasing superior/posterior intranasal corticosteroid deposition.
Objective
This study aims to evaluate the efficacy of EDS-FLU in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Methodology
A systematic literature review using Pubmed, Embase, Cochrane Library, and Web of Science was conducted to identify studies assessing the effect of EDS-FLU on outcomes in patients with CRSwNP.
Results
Of the initial 108 abstracts reviewed, 4 full-text articles were included. The 22-item sinonasal outcome test scores were significantly decreased in patients with CRSwNP after receiving EDS-FLU twice a day (93, 186, or 372 μg) for 16 weeks when compared with exhalation delivery system (EDS)-placebo (all P < .001). Patients with CRSwNP reported significant improvement of smell after receiving twice daily EDS-FLU twice a day (93, or 372 μg) for 4 weeks when compared with EDS-placebo (all P < .05). The proportions of patients achieving ≥1-point improvement in total polyp grade were significantly higher in EDS-FLU group and dose dependent, with the highest rates in the 372 μg group. The proportions of patients achieving polyp elimination were significantly higher in EDS-FLU group with the highest rates in the 372 μg group.
Conclusion
This is the first systematic review of the clinical outcomes in patients with CRSwNP treated with EDS-FLU. EDS-FLU produced significant improvements regarding the quality of life, smell, and endoscopic assessment of polyp grade.
LoftusCASolerZMKoochakzadehS, et al.Revision surgery rates in chronic rhinosinusitis with nasal polyps: Meta-analysis of risk factors. Int Forum Allergy Rhinol. 2020;10(2):199–207.
2.
HopkinsC. Chronic rhinosinusitis with nasal polyps. N Engl J Med. 2019;381(1):55–63.
3.
WuDBleierBWeiY. Definition and characteristics of acute exacerbation in adult patients with chronic rhinosinusitis: A systematic review. J Otolaryngol Head Neck Surg. 2020;49(1):62.
4.
WuDBleierBSWeiY. Current understanding of the acute exacerbation of chronic rhinosinusitis. Front Cell Infect Microbiol. 2019;9:415.
5.
BachertCMarpleBHosemannWCavaliereCWenWZhangN. Endotypes of chronic rhinosinusitis with nasal polyps: pathology and possible therapeutic implications.J Allergy Clin Immunol.2020;8(5):1514–1519.
6.
BachertCZhangNCavaliereCWeipingWGevaertEKryskoO. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145(3):725–739.
7.
ZhangYWangCHuangYLouHZhangL. Efficacy of short-term systemic corticosteroid therapy in chronic rhinosinusitis with nasal polyps: A meta-analysis of randomized controlled trials and systematic review. Am J Rhinol Allergy.2019;33(5):567–576.
8.
HanJKKernRC. Topical therapies for management of chronic rhinosinusitis: steroid implants. Int Forum Allergy Rhinol.2019;9(S1):S22–S26.
9.
ZhangYLouHWangYLiYZhangLWangC. Comparison of corticosteroids by 3 approaches to the treatment of chronic rhinosinusitis with nasal polyps. Allergy Asthma Immunol Res.2019;11(4):482–497.
10.
ScangasGAWuAWTingJY, et al.Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.Laryngoscope.2021;131(1):E26–E33.
11.
ScangasGARemenschneiderAKSuBMShrimeMGMetsonR. Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis. Laryngoscope.2017;127(1):29–37.
12.
BerggrenFJohanssonL. Cost effectiveness of nasal budesonide versus surgical treatment for nasal polyps. Pharmacoeconomics. 2003;21(5):351–356.
13.
WorkmanADBleierBS. Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost. J Otorhinolaryngol Head Neck Surg. 2020;6(4):230–234.
14.
ChenSZhouAEmmanuelBGarciaDRostaE. Systematic literature review of humanistic and economic burdens of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin.2020;36(11):1913–1926.
15.
BrownWCSeniorB. A critical look at the efficacy and costs of biologic therapy for chronic rhinosinusitis with nasal polyposis. Curr Allergy Asthma Rep. 2020;20(6):16.
16.
FokkensWJLundVJHopkinsC, et al. EPOS: European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58Suppl. 29:1–464.
17.
RudmikLSchlosserRJSmithTLSolerZM. Impact of topical nasal steroid therapy on symptoms of nasal polyposis: A meta-analysis. Laryngoscope.2012;122(7):1431–1437.
18.
DjupeslandPGSkrettingA. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv.2012;25(5):280–289.
19.
LeachCLKuehlPJChandRMcDonaldJD. Nasal deposition of HFA-beclomethasone, aqueous fluticasone propionate and aqueous mometasone furoate in allergic rhinitis patients.J Aerosol Med Pulm Drug Deliv.2015;28(5):334–340.
20.
EmanuelIABlaissMSMeltzerEOEvansPConnorA. Nasal deposition of ciclesonide nasal aerosol and mometasone aqueous nasal spray in allergic rhinitis patients. Am J Rhinol Allergy.2014;28(2):117–121.
21.
LamKTanBLavinJMeenEConleyD. Comparison of nasal sprays and irrigations in the delivery of topical agents to the olfactory Mucosa. Laryngoscope.2013;123(12):2950–2957.
22.
AggarwalRCardozoAHomerJJ. The assessment of topical nasal drug distribution. Clin Otolaryngol Allied Sci. 2004; 29(3):201–205.
23.
DjupeslandPG. Nasal drug delivery devices: Characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res. 2013;3(1):42–62.
24.
AndrewsAEBrysonJMRowe-JonesJM. Site of origin of nasal polyps: relevance to pathogenesis and management. Rhinology. 2005;43(3):180–184.
25.
LarsenPLTosM. Origin of nasal polyps: An endoscopic autopsy study. Laryngoscope.2004;114(4):710–719.
26.
MasakiMTanakaY. Nasal polyps in the olfactory cleft. Laryngoscope.1998;108(8):1243–1246.
27.
BhattacharyyaNOrlandiRRGrebnerJMartinsonM. Cost burden of chronic rhinosinusitis: A claims-based study. Otolaryngol Head Neck Surg.2011;144(3):440–445.
28.
BaguleyCBrownlowAYeungKPrattESacksRHarveyR. The fate of chronic rhinosinusitis sufferers after maximal medical therapy. Int Forum Allergy Rhinol.2014;4(7):525–532.
29.
ChongLYHeadKHopkinsCPhilpottCBurtonMJSchilderAG. Different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011994.
30.
GraysonJWHarveyRJ. Topical corticosteroid irrigations in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019;9(S1):S9–S15.
31.
TanNCWPsaltisAJ. Latest developments on topical therapies in chronic rhinosinusitis.Curr Opin Otolaryngol Head Neck Surg. 2020;28(1):25–30.
32.
KennedyDW. Additional options in chronic rhinosinusitis management. Int Forum Allergy Rhinol. 2018;8(8):867–868.
33.
HarveyRJDebnathNSrubiskiABleierBSchlosserRJ. Fluid residuals and drug exposure in nasal irrigation. Otolaryngol Head Neck Surg. 2009;141(6):757–761.
34.
WangCLouHWangX, et al.Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol.2015;135(4):922–929.
35.
DemirelTOrhanKSKeleşNDeğerK. Comparison of the efficacy of nasal drop and nasal spray applications of fluticasone propionate in nasal polyps. Kulak Burun Bogaz Ihtis Derg. 2008;18(1):1–6.
36.
MerkusPEbbensFAMullerBFokkensWJ. Influence of anatomy and head position on intranasal drug deposition. Eur Arch Otorhinolaryngol. 2006;263(9):827–832.
37.
DjupeslandPGMessinaJCMahmoudRA. Breath powered nasal delivery: A new route to rapid headache relief. Headache. 2013;53Suppl 2:72–84.
38.
XiJWangZSiXAZhouY. Nasal dilation effects on olfactory deposition in unilateral and bi-directional deliveries: In vitro tests and numerical modeling. Eur J Pharm Sci.2018;118:113–123.
39.
DongJShangYInthavongKChanHKTuJ. Numerical comparison of nasal aerosol administration systems for efficient nose-to-brain drug delivery. Pharm Res. 2017; 35(1):5.
40.
KuanECKovacsAJWorkmanADBossoJVAdappaND. Efficacy of fluticasone exhalation delivery system in the management of chronic rhinosinusitis: What is the evidence?Int Forum Allergy Rhinol.2019;9(S1):S16–S21.
41.
KovacsAJGoshtasbiKKuanEC. What is the evidence for fluticasone exhalation delivery system in chronic rhinosinusitis?Curr Opin Otolaryngol Head Neck Surg. 2020;28(1):14–17.
42.
HigginsJPAltmanDGGøtzschePC, et al.The Cochrane Collaboration's Tool for assessing risk of bias in randomised trials. Br Med J.2011;343:d5928.
43.
PalmerJNJacobsonKWMessinaJCKosik-GonzalezCDjupeslandPGMahmoudRA. EXHANCE-12: 1-year study of the exhalation delivery system with fluticasone (EDS-FLU) in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2018; 8(8):869–876.
44.
SindwaniRHanJKSoteresDF, et al.NAVIGATE I: Randomized, placebo-controlled, double-blind trial of the exhalation delivery system with fluticasone for chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy.2019;33(1):69–82.
45.
LeopoldDAElkayamDMessinaJCKosik-GonzalezCDjupeslandPGMahmoudRA. NAVIGATE II: randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. J Allergy Clin Immunol. 2019; 143(1):126–134.
46.
SherMRStevenGCRomettJL, et al.EXHANCE-3: A cohort study of the exhalation delivery system with fluticasone for chronic sinusitis with or without nasal polyps. Rhinology. 2020;58(1):25–35.
47.
BhattacharyyaNVilleneuveSJoishVN, et al.Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope.2019;129(9):1969–1975.
48.
SmithKAOrlandiRRRudmikL. Cost of adult chronic rhinosinusitis: A systematic review. Laryngoscope.2015; 125(7):1547–1556.
49.
RudmikL. Economics of chronic rhinosinusitis. Curr Allergy Asthma Rep.2017;17(4):20.
50.
SeniorBASchlosserRJBossoJSolerZM, editors. Efficacy of the exhalation delivery system with fluticasone in patients who remain symptomatic on standard nasal steroid sprays.Int Forum Allergy Rhinol.2021;11(5):837–845.
51.
KohliPNaikANHarruffEENguyenSASchlosserRJSolerZM. The prevalence of olfactory dysfunction in chronic rhinosinusitis. Laryngoscope.2017;127(2):309–320.
52.
LitvackJRFongKMaceJJamesKESmithTL. Predictors of olfactory dysfunction in patients with chronic rhinosinusitis. Laryngoscope.2008;118(12):2225–2230.
53.
WuDBleierBSWeiY. Temporary olfactory improvement in chronic rhinosinusitis with nasal polyps after treatment.Eur Arch Oto-Rhino-Laryngol.2018;275(9):2193–2202.
54.
HauserLJChandraRKLiPTurnerJH. Role of tissue eosinophils in chronic rhinosinusitis–associated olfactory loss.Int Forum Allergy Rhinol.2017;7(10):957–962.
55.
WuDLiYBleierBSWeiY. Superior turbinate eosinophilia predicts olfactory decline in patients with chronic rhinosinusitis.Ann Allergy Asthma Immunol.2020;125(3):304–310.
56.
DjupeslandPG. Nasal drug delivery devices: Characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res.2013;3(1):42–62.
57.
DjupeslandPGSkrettingAWinderenMHolandT. Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope.2006;116(3):466–472.
58.
BossoJPalmerJDjupeslandPGuerreroGSacksH. Efficient topical steroid delivery to grades 1 and 2 nasal polyps in the Osteomeatal Complex (OMC): deposition patterns with Exhalation Delivery System (EDS) and conventional Intranasal Spray (INS) visualized with fluorescein in silicone cast. J Allergy Clin Immunol.2020;145(2):AB149.
59.
KovacsAJAdappaNDKuanEC. Exhalation delivery systems for application of intranasal corticosteroids. Ear Nose Throat J. 2021;100(5):309–313.
60.
OrlandiRRKingdomTTSmithTL, et al. International consensus statement on rhinology and allergy: rhinosinusitis. Int Forum Allergy Rhinol. 2021;11(3):213–739.
61.
BachertCMarpleBSchlosserRJ, et al. Adult chronic rhinosinusitis. Nat Rev Dis Primers.2020;6(1):86.
62.
NaclerioRBaroodyFBachertC, et al.Clinical research needs for the management of chronic rhinosinusitis with nasal polyps in the new era of biologics: a national institute of allergy and infectious diseases workshop. J Allergy Clin Immunol Pract. 2020;8(5):1532–1549.
